Amnesia Haze

Despite the yearly earnings for the cannabis industry, insurers only wrote out about 250 million in policies and in many cases are charging far more than typical retailers with extreme limits in place. This might not be of significant importance to consumers, but if insurers do get a chance to play with the cannabis industry – it could revolutionize the industry within a matter of months.

The big fish are supposed to gobble up the small fish in business.  The big publicly traded cannabis companies have all the cash and equity to do billion-dollar deals, so how is a relatively small tech and delivery company swimming upstream and buying an MSO? One, it tells us investors are shifting their value proposition from “let’s invest in dispensaries” to “let’s invest in technology that can deliver and create cannabis orders on the cheap, hence creating a moat around margins”. EAZE recently raised $35 million in order to facilitate this buyout.

However, no one else has done more for cannabis research than Dr. Raphael Mechoulam. The Israeli chemist, researcher, and professor of Medicinal Chemistry has devoted much of his life to studying marijuana. So much so, that he was given the nickname, “Godfather of Cannabis Research” early on. In 2016, his efforts were acknowledged and he was thus given the Lifetime Achievement Award in Cambridge, because of several decades of breakthrough research. That is just one of the many awards he has been given during his lifetime.